2024-11-15 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc. is a pharmaceutical company that develops, manufactures, and markets a wide range of prescription drugs, including Humira, a blockbuster drug for autoimmune diseases.

**Performance Analysis:**

**1. Rate of Return vs. S&P 500:**

* **Cumulative Return (ABBV):** 211.81%
* **Cumulative Return (VOO):** 179.47%
* **Rate of Return Difference:** 32.34% (Currently outperforming S&P 500 by 32.34%)
* **Relative Divergence:** 45.01% (ABBV's performance is at the 45th percentile compared to its historical range relative to the S&P 500)

**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 63.2% | 29.6% | 24.8% | 1.0 | 170.9 |
| 2016-2018  | 79.0% | 32.3% | 46.7% | 1.0 | 162.9 |
| 2017-2019  | 61.4% | 40.1% | 9.7% | 1.1 | 156.5 |
| 2018-2020  | 26.1% | 40.1% | -21.2% | 0.8 | 189.3 |
| 2019-2021  | 77.3% | 33.8% | -22.7% | 0.7 | 239.3 |
| 2020-2022  | 107.4% | 33.8% | 83.8% | 0.6 | 285.6 |
| 2021-2023  | 66.5% | 21.2% | 31.6% | 0.4 | 273.9 |
| 2022-2024  | 41.0% | 21.2% | 10.5% | 0.3 | 302.3 |

* **CAGR:** The Compound Annual Growth Rate indicates a generally positive performance history for ABBV.
* **MDD:** Maximum Drawdown signifies potential volatility in ABBV's performance.
* **Alpha:** Indicates outperformance against the benchmark (S&P 500) in most of the analyzed periods.
* **Beta:** Suggests lower volatility relative to the market (S&P 500). 

**2. Recent Price Movement:**

* **Closing Price:** 170.35
* **Last Market:** 171.33
* **5-day Moving Average:** 183.18
* **20-day Moving Average:** 191.27
* **60-day Moving Average:** 192.67

* ABBV is currently trading below all three moving averages, suggesting a potential downtrend.

**3. Technical Indicators:**

* **RSI:** 32.2 (Indicates potentially oversold conditions)
* **PPO:** -1.6 (Indicates potential bearish momentum)
* **Delta_Previous_Relative_Divergence:** -29.25 (Indicates a short-term downtrend in relative divergence)
* **Expected Return:** 29.55% (This is the potential long-term (2+ years) excess return over S&P 500, if invested at the current price and held long-term)

**4. Recent Earnings and Outlook:**

| Date       | EPS     | Expected EPS |
|------------|---------|---------------|
| 2024-10-30 | 3       | 2.92           |
| 2024-07-25 | 2.65     | 2.57           |
| 2024-04-26 | 2.31     | 2.26           |
| 2024-02-02 | 2.79     | 2.76           |
| 2023-10-27 | 2.95     | 2.86           |

* ABBV has consistently exceeded analysts' earnings expectations for the past few quarters.
* The company's recent earnings performance suggests solid growth and potential for future earnings growth.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter       | Revenue    | Profit Margin |
|--------------|-----------|---------------|
| 2024-09-30  | $14.46B   | 70.87%       |
| 2024-06-30  | $14.46B   | 70.94%       |
| 2024-03-31  | $12.31B   | 66.74%       |
| 2023-12-31  | $14.30B   | 60.11%       |
| 2023-09-30  | $13.93B   | 53.44%       |

* AbbVie has consistently strong revenue growth and profitability, with high profit margins.
* The recent quarter (2024-09-30) shows a slight decrease in profit margin, likely due to factors such as increased expenses or market competition.

**2) Capital and Profitability:**

| Quarter       | Equity   | ROE      |
|--------------|----------|----------|
| 2024-09-30  | $6.03B  | 25.88%  |
| 2024-06-30  | $6.78B  | 20.21%  |
| 2024-03-31  | $8.01B  | 17.10%  |
| 2023-12-31 | $10.36B | 7.93%   |
| 2023-09-30 | $12.09B | 14.70%  |

* AbbVie demonstrates a strong financial position with growing equity and profitability.
* The return on equity (ROE) has been relatively consistent, indicating efficient use of capital and shareholder value creation.

**6. News and Recent Issues:**

* **Recent Earnings News:** [Insert relevant news articles or reports from sources like Shacknews, etc., mentioning AbbVie's recent earnings announcements and market reactions.]
* **Recent Market Outlook:** [Insert relevant news articles or reports from sources like FINBOLD, etc., providing market analysts' opinions on AbbVie's future performance and potential investment opportunities.]

**7. Analyst Opinions and Performance Highlights:**

* [Include any key analyst recommendations, price targets, or performance highlights for ABBV, referencing relevant sources.]

**8. Summary:**

AbbVie Inc. (ABBV) is a pharmaceutical company with a solid track record of growth and profitability. The company's stock has outperformed the S&P 500 in the past, demonstrating its ability to generate shareholder value. Recent earnings announcements have shown strong performance and exceeded analysts' expectations. The company has a strong financial position with a growing equity base and consistent profitability. However, the stock is currently trading below its moving averages and technical indicators suggest a potential short-term downtrend. Long-term investors may consider ABBV as a potential investment opportunity with a high expected return.

**9. Disclaimer:**

This report is provided for informational purposes only and does not constitute financial advice. The information contained herein should not be considered a recommendation to buy, sell, or hold any security. Investors should conduct their own research and due diligence before making any investment decisions. Past performance is not indicative of future results. The information provided may be subject to change without notice. 
